Intra-Cellular Therapies, Inc.
Intra-Cellular Therapies, Inc.
Explore linked clinical trials.14 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of JNJ-99245354 (ITI-1284) as an Adjunctive Treatment in Participants With Generalized Anxiety Disorder (GAD) Who Have an Inadequate Response to GAD Treatment | anxiety disorder, generalized anxiety disorder, psychiatric disorder | Not yet recruiting | Phase 3 | 2026-10-02 | NCT07856420 | |
| A Study to Asses Safety and Tolerability of ITI-1284 Given Alone or as an Additional Treatment in Participants With Generalized Anxiety Disorder (GAD) | anxiety disorder, generalized anxiety disorder, psychiatric disorder | Recruiting | Phase 3 | 2026-09-29 | NCT07807865 | |
| A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia | Agitation Associated With Alzheimer's Dementia | Recruiting | Phase 2 | 2026-09-29 | NCT06651567 | |
| A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease | Alzheimer disease, Psychotic Disorders, Schizophrenia Spectrum and Other Psychotic Disorders, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Recruiting | Phase 2 | 2026-09-29 | NCT06540833 | |
| Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) in Pediatric Patients | Irritability Associated With Autism Spectrum Disorder | Recruiting | Phase 3 | 2026-09-25 | NCT06706674 | |
| Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder | anxiety disorder, generalized anxiety disorder, psychiatric disorder | Recruiting | Phase 2 | 2026-09-25 | NCT06701903 | |
| Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder in Pediatric Patients | Irritability Associated With Autism Spectrum Disorder | Recruiting | Phase 3 | 2026-09-25 | NCT06690398 | |
| Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder | anxiety disorder, generalized anxiety disorder, psychiatric disorder | Recruiting | Phase 2 | 2026-09-25 | NCT06480383 | |
| Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients | Bipolar and Related Disorders, bipolar disorder, mood disorder, psychiatric disorder | Recruiting | Phase 3 | 2026-09-25 | NCT06372964 | |
| Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder | Bipolar and Related Disorders, Schizophrenia Spectrum and Other Psychotic Disorders, autism spectrum disorder, bipolar disorder, mood disorder, neurodevelopmental disorder, pervasive developmental disorder, psychiatric disorder, schizophrenia | Recruiting | Phase 3 | 2026-09-25 | NCT06229210 | |
| Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder | depressive disorder, major depressive disorder, mood disorder, psychiatric disorder | Recruiting | Phase 3 | 2026-09-25 | NCT05850689 | |
| Lumateperone for Late-Life Depression | Depressive Disorder, Treatment-Resistant, depressive disorder, major depressive disorder, mood disorder, psychiatric disorder | Recruiting | Phase 3 | 2026-09-16 | NCT07623135 | |
| A Study of Lumateperone Versus Placebo in Participants With Major Depressive Disorder | depressive disorder, major depressive disorder, mood disorder, psychiatric disorder | Not yet recruiting | Phase 3 | 2026-08-31 | NCT07747389 | |
| Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia | Psychotic Disorders, Schizophrenia Spectrum and Other Psychotic Disorders, psychiatric disorder, schizophrenia | Recruiting | Phase 4 | 2026-05-22 | NCT06174116 |